These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6346910)

  • 21. Continuation treatment with adjunctive imipramine in schizophrenia.
    Siris SG; Bermanzohn PC; Mason SE; Shuwall MA; Aseniero MA
    Psychopharmacol Bull; 1992; 28(3):303-7. PubMed ID: 1480734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial.
    Goff DC; Arana GW; Greenblatt DJ; Dupont R; Ornsteen M; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1991 Apr; 11(2):106-12. PubMed ID: 2056136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of withdrawal dyskinesia.
    Gardos G
    Am J Psychiatry; 1979 Aug; 136(8):1099. PubMed ID: 464147
    [No Abstract]   [Full Text] [Related]  

  • 24. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.
    Moreau A; Jones BD; Banno V
    Can J Psychiatry; 1986 May; 31(4):339-41. PubMed ID: 3708528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluphenazine decanoate and tardive dyskinesia: a possible association.
    Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
    Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letter: Potentiation of tardive dyskinesia: possible drug interaction.
    Marriett PF
    Br Med J; 1975 Apr; 2(5963):139. PubMed ID: 1125709
    [No Abstract]   [Full Text] [Related]  

  • 30. Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder.
    Siris SG; Aronson A; Sellew AP
    Biol Psychiatry; 1989 Feb; 25(4):485-8. PubMed ID: 2649158
    [No Abstract]   [Full Text] [Related]  

  • 31. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine.
    Hebenstreit GF; Fellerer K; Fichte K; Fischer G; Geyer N; Meya U; Sastre-y-Hernández M; Schöny W; Schratzer M; Soukop W
    Pharmacopsychiatry; 1989 Jul; 22(4):156-60. PubMed ID: 2668980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case report of vomiting related to the interactions of antipsychotics and benztropine.
    Schaffer CB; Shahid A; Javaid JI; Davis JM
    Am J Psychiatry; 1981 Jun; 138(6):833-5. PubMed ID: 6113771
    [No Abstract]   [Full Text] [Related]  

  • 33. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics.
    Caradoc-Davies G; Menkes DB; Clarkson HO; Mullen PE
    Aust N Z J Psychiatry; 1986 Jun; 20(2):225-32. PubMed ID: 2876700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
    Russell N; Landmark J; Merskey H; Turpin T
    Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics.
    Winslow RS; Stillner V; Coons DJ; Robison MW
    Am J Psychiatry; 1986 Jun; 143(6):706-10. PubMed ID: 2872822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The withdrawal of benztropine mesylate in chronic schizophrenic patients.
    Baker LA; Cheng LY; Amara IB
    Br J Psychiatry; 1983 Dec; 143():584-90. PubMed ID: 6362765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.
    Siris SG; Cooper TB; Rifkin AE; Brenner R; Lieberman JA
    Am J Psychiatry; 1982 Jan; 139(1):104-6. PubMed ID: 7055248
    [No Abstract]   [Full Text] [Related]  

  • 40. Cholinergic syndrome following anticholinergic withdrawal in a schizophrenic patient abusing marijuana.
    Tandon R; Dutchak D; Greden JF
    Br J Psychiatry; 1989 May; 154():712-4. PubMed ID: 2597866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.